Skip to main content

Biohit Oyj (BIOBV.HE)

Nasdaq Helsinki Healthcare BiotechnologyView data quality →
57.7Fair

ValueMarkers Composite Index

Top 70%#13,553 of 44,707
Undervalued

82% below intrinsic value ($15)

UndervaluedFair ValueOvervalued
Piotroski
1/9
Weak
Beneish
-2.26
Low Risk
Altman
6.62
Safe
DCF Value
$15
Undervalued
ROIC
17.5%
Strong
P/E
12.8
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Biohit Oyj (BIOBV.HE) — VMCI valuation read

The headline on Biohit Oyj (BIOBV.HE) is a 58/100 VMCI score, set against a Healthcare sector median of 50. That 8-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

BIOBV.HE insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** BIOBV.HE trades at 27.0x earnings, 50% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -2.1x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on BIOBV.HE.

BIOBV.HE fell 3.2% over the trailing 7 days, with a -24.0% read on a 30-day basis.

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.

CEO: Osmo Antero Suovaniemi46 employeesFIwww.biohithealthcare.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BIOBV.HE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.